KRAS and colorectal carcinoma: In a genome-scale CRISPR-Cas9 modifier screening, neurofibromin 1 (NF1) was identified as an important regulator of the resistance to EGFR inhibitors in NRAS/KRAS/BRAFV600-wildtype CRC cells (156).